Elevated glutamine but not glutamate is associated with clozapine eligibility in an early psychosis sample

Dados Bibliográficos

ID15519679
AutoresMaxwell Seward (Dalhousie University, autor correspondente), Esther Puiras (Nova Scotia Health Authority), Temi Toba-Oluboka (0000-0001-6047-0766, Nova Scotia Health Authority), Candice E Crocker (0000-0001-8102-1716, Dalhousie University), Philip G Tibbo (0000-0002-2070-6495, Dalhousie University), Kara Dempster (0000-0002-5903-5051, Dalhousie University)
Ano2026
Volume17
Páginas1762696-1762696
Data de publicação2026-02-24
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoFrontiers in Psychiatry (JOURNAL)
Identificadores do periódicoISSN: 1664-0640 • E-ISSN: 1664-0640
EditoraFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2026.1762696
PMID41816535
OpenAlexW7131313260
IdiomaEN
Referências citadas66

While elevated ACC glutamate has been associated with poor response to antipsychotic medications in early psychosis samples, this is the first study to explore the association with clozapine eligibility. Contrary to our hypothesis, ACC glutamate was not higher in the CE group. However, glutamine, a precursor to glutamate, was higher in the CE group, in line with previous studies that have found elevated glutamatergic metabolites to be associated with poor treatment response to antipsychotic medication. Our results support future studies to further characterize the neurobiology of clozapine eligibility in early-phase psychosis to assist in the timely initiation of clozapine to maximize outcomes

Antipsychotic · Clozapine · Early psychosis · Glutamate receptor · Glutamine · Psychosis · Schizophrenia (object-oriented programming · Functional Brain Connectivity Studies · Schizophrenia research and treatment · Treatment of Major Depression